Clinical–alimentary tractSurvival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based Study
Section snippets
Materials and Methods
All incident MDETs diagnosed in adults (aged 15–99 years) in the 55 million population of England and Wales during the 14-year period between January 1, 1986, and December 31, 1999, were linked with information from the National Health Service Central Register4 on deaths up to December 31, 2001, by the National Cancer Registry at the Office for National Statistics, and an anonymized extract was provided. Population-based regional cancer registries covering the entire territory of England and
Characteristics of MDETs
The 4104 endocrine carcinomas represented 0.6% of all incident digestive cancers in men during 1986–1999 and 0.7% in women (sex ratio, 0.96). MDETs were grouped into well-differentiated tumors (78.8%) and small cell tumors (21.2%; Table 1). Women were significantly more common among those with small cell tumors (58.8%; P < .001), but the sex ratio was close to unity for well-differentiated tumors. The mean age at diagnosis was 62.8 years (SD, 15.6 years) for patients with well-differentiated
Discussion
This study confirms that MDETs are rare, representing <1% of all malignancies of the digestive tract. The mean age at diagnosis of well-differentiated MDETs (63 years) is lower than for other digestive tract cancers (about 70 years for epithelial tumors). In hospital case series, the mean age at diagnosis is generally lower than in our study, suggesting that the oldest patients with MDETs are rarely seen in specialized centers.16, 17 One of the interests of this population-based study is to
References (31)
- et al.
Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas
Surgery
(2005) - et al.
Small cell carcinoma of the esophagusThe Massachusetts General Hospital experience, 1978 to 1993
Chest
(1995) - et al.
Small cell neuroendocrine carcinoma of the colon and rectum: clinical, histologic, and ultrastructural study and immunohistochemical comparison with cloacogenic carcinoma
Hum Pathol
(1987) - et al.
- et al.
Small-cell carcinomas of the gastrointestinal tract: a review
J Clin Oncol
(2004) - et al.
Incidence and management of malignant digestive endocrine tumours in a well-defined French population
Gut
(2004) - Office for National Statistics. Census 2001 homepage. Volume 2003. Available at:...
Cancer registration in England and Wales: some aspects relevant to interpretation of the data
J R Statist Soc A
(1986)- et al.
Cancer trends in England and Wales 1950–1999
(2001) International classification of diseases for oncology
(1992)
Deprivation indices: their interpretation and use in relation to health
J Epidemiol Common Health
Measuring multiple deprivation at the small area level: The indices of deprivation 2000
Welsh index of multiple deprivation
Relative survival and the estimation of net survival: elements for further discussion
Stat Med
Census: small area statistics and local base statistics
Cited by (102)
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study
2022, European Journal of CancerCitation Excerpt :The incidence of neuroendocrine tumours (NETs) is increasing, and their prevalence is high [1]. Duodeno-pancreatic (DP) NETs are the second most frequent digestive NET, and 5-year survival for these tumours is about 30% in metastatic patients [1,2]. More than half of these tumours are diagnosed at a locally advanced or metastatic stage, and 75% of patients have liver metastases [3].
Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study
2022, European Journal of CancerA rare rarity: Neuroendocrine tumor of the esophagus
2019, Critical Reviews in Oncology/HematologyA population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours
2017, Canadian Journal of SurgeryCitation Excerpt :The sex distribution did not vary significantly as a function of year in our study. Outcomes analyses historically used different staging criteria derived from different sources, including the American Joint Committee on Cancer (AJCC), European Neuroendocrine Tumor Society (ENETS) or the SEER databases, each with varying abilities to predict tumour behaviour.6–11 To facilitate comparison in the present study we use a single, simplified staging system comparable to that used by SEER, documenting local, regional and distant disease among the different tumour sites.